CXCL12 and neoplasm: CXCR4 antagonists disrupt the CXCR4/CXCL12 signaling pathway, thereby enhancing the efficacy of chemotherapy by increasing drug delivery to the tumor and reducing resistance mechanisms driven by hypoxia and stromal interactions [41].